

MYRIAD GENETICS INC  
Form 8-K  
May 02, 2005

[QuickLinks](#) -- Click here to rapidly navigate through this document

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **May 2, 2005**

**MYRIAD GENETICS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**0-26642**  
(Commission  
File Number)  
**320 Wakara Way**  
**Salt Lake City, Utah 84108**  
(Address of principal executive offices) (Zip Code)

**87-0494517**  
(IRS Employer  
Identification No.)

Registrant's telephone number, including area code: **(801) 584-3600**

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**ITEM 8.01 Other Events**

On May 2, 2005, Myriad Genetics, Inc. announced the preliminary results of its Phase 2 clinical trial of Flurizan for the treatment of patients with mild to moderate Alzheimer's disease. The press release is attached hereto as an exhibit to this Current Report on Form 8-K and is

## Edgar Filing: MYRIAD GENETICS INC - Form 8-K

being filed pursuant to this Item 8.01 as Exhibit 99.1 to this Current Report on Form 8-K.

### ITEM 9.01 Financial Statements and Exhibits.

(c)

The following exhibit is filed with this report:

Exhibit Number	Description
99.1	The Registrant's press release dated May 2, 2005.

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

#### MYRIAD GENETICS, INC.

Date: May 2, 2005

By: /s/ PETER D. MELDRUM

Peter D. Meldrum  
President and Chief Executive Officer

### EXHIBIT INDEX

Exhibit Number	Description
99.1	The Registrant's press release dated May 2, 2005.

QuickLinks

[ITEM 8.01 Other Events](#)

[ITEM 9.01 Financial Statements and Exhibits.](#)

[SIGNATURES](#)

[EXHIBIT INDEX](#)